Designating the first full week in May as Tardive Dyskinesia Awareness Week.
Sponsors
Legislative Progress
In CommitteeMr. Mullin (for himself and Mr. Padilla) submitted the following …
Summary
What This Bill Does
This Senate resolution officially designates the first full week in May as "Tardive Dyskinesia Awareness Week." Tardive dyskinesia (TD) is a potentially irreversible movement disorder that can develop as a side effect of antipsychotic medications commonly prescribed for schizophrenia, bipolar disorder, and other mental health conditions. The resolution aims to raise public awareness about this condition and emphasize the importance of routine screening and early detection.
Who Benefits and How
Individuals with mental health conditions who take antipsychotic medications benefit from increased awareness and screening, which can lead to earlier detection and intervention before TD becomes severe or irreversible. Mental health advocacy organizations and patient support groups gain official recognition for their awareness campaigns and may see increased participation and funding opportunities. Healthcare providers, particularly psychiatrists, receive reinforcement for implementing routine TD screening protocols, potentially improving patient outcomes.
Who Bears the Burden and How
This is a ceremonial resolution with no direct regulatory requirements or appropriations, so there are minimal burdens. Pharmaceutical companies manufacturing antipsychotic medications may face indirect reputational concerns as awareness of side effects increases, though the resolution does not impose any restrictions or reporting requirements on them. Mental health clinicians may feel encouraged to adopt more rigorous screening practices, which could add time to patient appointments, though this is framed as beneficial rather than burdensome.
Key Provisions
- Officially designates the first full week in May each year as "Tardive Dyskinesia Awareness Week"
- Underscores the importance of early detection and intervention to improve outcomes for individuals with mental health conditions
- Supports efforts to raise public awareness about the causes and symptoms of tardive dyskinesia
- Promotes routine screening for tardive dyskinesia among patients prescribed antipsychotic medications
Evidence Chain:
This summary is derived from the structured analysis below. See "Detailed Analysis" for per-title beneficiaries/burden bearers with clause-level evidence links.
Primary Purpose
Designates the first full week in May as Tardive Dyskinesia Awareness Week to promote awareness and early detection of this antipsychotic medication side effect
Policy Domains
Legislative Strategy
"Ceremonial resolution to raise awareness about medication side effects and promote screening practices"
Likely Beneficiaries
- Individuals with mental health conditions
- Mental health advocacy organizations
- Healthcare providers specializing in psychiatry
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
Key Definitions
Terms defined in this bill
A movement disorder that can develop as a side effect of antipsychotic medications, requiring routine screening for early detection
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology